The Pandora Project: Cost of hypertension from a general practitioner database

被引:8
作者
Berto, P
Degli Esposti, E
Ruffo, P
Buda, S
Degli Esposti, L
Sturani, A
Lopatriello, S
机构
[1] PBE Consulting, IT-37121 Verona, Italy
[2] SM Croci Hosp, Dept Nephrol, Ravenna, Italy
[3] Pfizer Italiana, Dept Outcome Res, Rome, Italy
[4] CliCon Srl, Ravenna, Italy
关键词
cost-of-illness; costs; economics; hypertension;
D O I
10.1080/080370502760050386
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Aim: The Pandora Project is a longitudinal database - implemented by general practitioners since June 1997 in the Ravenna area (Italy) - providing information on patients with hypertension. Data from 1651 patients were followed up for 1 year in order to investigate the cost of hypertension. Only direct medical costs were considered in the perspective of the National Healthcare System. Findings: At enrolment, 552 patients were classified as normotensive, 1099 as hypertensive. After I year, among normotensive group, 352 patients remained normotensive and 200 became hypertensive; among hypertensive group, 323 patients became normotensive and 776 remained hypertensive. The average total cost per patient at follow-up was 779.59 Euros. About 46% of total cost was due to anti-hypertensive therapy, irrespective of the evolution of blood pressure levels registered, whilst other direct costs represented 54% of total patient cost in all cohorts. It is possible that co-morbidities play a significant role in this situation. Patient aged 80-89 years generate higher costs. Even if further investigation is needed on the burden of co-morbidity on a per-patient cost of hypertension, this work provides evidence that the average total cost per patient is likely to increase with age and co-morbidities.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 23 条
[1]
ALLI C, 1997, G ITAL CARDIOL S1, V27, P41
[2]
PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313
[3]
Coca A, 1998, J HYPERTENS, V16, pS45
[4]
Dwivedi S, 2000, J Assoc Physicians India, V48, P1047
[5]
*EP COLL GROUP, 1985, G ITAL CARDIOL, V15, P842
[6]
EPOSTI ED, 1999, AM J HYPERTENS, V12, P790
[7]
EPOSTI ED, 2001, J HUM HYPERTENS, V15, P329
[8]
Benefits of adherence to anti-hypertensive drug therapy [J].
Flack, JM ;
Novikov, SV ;
Ferrario, CM .
EUROPEAN HEART JOURNAL, 1996, 17 :16-20
[9]
GIFFORD RW, 1993, ARCH INTERN MED, V153, P154
[10]
Medical care expenditures for hypertension, its complications, and its comorbidities [J].
Hodgson, TA ;
Cai, LM .
MEDICAL CARE, 2001, 39 (06) :599-615